TROPION-PanTumor03: Dato-DXd plus rilvegostomig shows promising activity in patients with advanced urothelial cancer

ELCC 2025

Lung, Respiratory and Thoracic Cancer

TROPION-Lung01: Favorable QoL outcomes with Dato-DXd in patients with pretreated advanced or metastatic NSCLC

ESMO 2025

Breast Cancer

TROPION-Breast02: First-line Dato-DXd shows superiority over chemotherapy in patients with TNBC ineligible for immunotherapy

Genitourinary Cancer

Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study

Lancet Oncol

Gupta S, Loriot Y, Van der Heijden MS, Bedke J, Valderrama BP, Kikuchi E, Fléchon A, Petrylak D, De Santis M, Galsky MD, Lee JL, Swami U, Sridhar SS, De Giorgi U, Wright P, Shih V, Lu YT, Guan X, Dillon R, Shetty A, Moreno BH, Beaumont JL, Purnajo I, McManus S, Powles T

doi: 10.1016/S1470-2045(25)00158-5

CHICAGO 2025

Gynecologic Cancer

RUBY: Dostarlimab plus carboplatin and paclitaxel shows no detrimental effect on QoL in patients with primary advanced or recurrent endometrial cancer

Genitourinary Cancer

Updated Findings Support Enfortumab Vedotin plus Pembrolizumab as Standard of Care in Advanced Urothelial Cancer

SABCS 2024

Breast Cancer

SERENA-1: Camizestrant plus ribociclib show encouraging clinical activity in women with ER-positive, HER2-negative advanced breast cancer

ESMO 2025

Breast Cancer

DESTINY-Breast09: T-DXd plus placebo shows superior efficacy over THP across subgroups in HER2-positive advanced or metastatic breast cancer

Breast Cancer

Efficacy, safety, and patient-reported outcomes across young to older age groups of patients with HR+/HER2- advanced breast cancer treated with ribociclib plus endocrine therapy in the randomized MONALEESA-2, -3, and -7 trials

Eur J Cancer

Hart LL, Im SA, Tolaney SM, Campone M, Pluard T, Sousa B, Freyer G, Decker T, Kalinsky K, Sopher G, Gao M, Hu H, Kuemmel S

doi: 10.1016/j.ejca.2025.115225

SABCS 2024

Breast Cancer

Capivasertib plus fulvestrant in patients with AI-resistant, HR-positive, HER2-negative advanced breast cancer: Exploratory analyses of PTEN deficiency in CAPItello-291

Related content

TROPION-Lung01: Favorable QoL outcomes with Dato-DXd in patients with pretreated advanced or metastatic NSCLC

TROPION-Breast02: First-line Dato-DXd shows superiority over chemotherapy in patients with TNBC ineligible for immunotherapy

Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study

RUBY: Dostarlimab plus carboplatin and paclitaxel shows no detrimental effect on QoL in patients with primary advanced or recurrent endometrial cancer

Updated Findings Support Enfortumab Vedotin plus Pembrolizumab as Standard of Care in Advanced Urothelial Cancer

SERENA-1: Camizestrant plus ribociclib show encouraging clinical activity in women with ER-positive, HER2-negative advanced breast cancer

DESTINY-Breast09: T-DXd plus placebo shows superior efficacy over THP across subgroups in HER2-positive advanced or metastatic breast cancer

Efficacy, safety, and patient-reported outcomes across young to older age groups of patients with HR+/HER2- advanced breast cancer treated with ribociclib plus endocrine therapy in the randomized MONALEESA-2, -3, and -7 trials

Capivasertib plus fulvestrant in patients with AI-resistant, HR-positive, HER2-negative advanced breast cancer: Exploratory analyses of PTEN deficiency in CAPItello-291